Adcendo
Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment
$75MSeries C
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
Pitching Logos Capital? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room